<DOC>
	<DOCNO>NCT02500316</DOCNO>
	<brief_summary>Protocol CP-4-004-EXT design open-label extension study assess long-term MOD-4023 administration . It open subject complete Phase 2 study child growth hormone deficiency ( CP-4-004 ) .</brief_summary>
	<brief_title>Long Term Follow Study Long-acting hGH ( MOD-4023 ) Growth Hormone Deficient Children</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<criteria>Patients complete first year treatment main study allow enter ( Long Term ) Open Label Extension ( OLE ) study . 1 . Children past present intracranial tumor growth confirm MRI scan ( contrast ) . 2 . History radiation therapy chemotherapy . 3 . Malnourished child define : 1 . Serum albumin low limit normal ( LLN ) accord reference range central laboratory ; 2 . Serum iron lower limit normal ( LLN ) accord reference range central laboratory ; 3 . BMI &lt; 2 Standard Deviation age sex ; 4 . Children psychosocial dwarfism . 5 . Children born small gestational age ( SGA birth weight and/or birth length &lt; 2 SD gestational age ) . 6 . Presence antihGH antibody screen . 7 . Any clinically significant abnormality likely affect growth ability evaluate growth , , limit , chronic disease like renal insufficiency , spinal cord irradiation , etc . 8 . Patients diabetes mellitus . 9 . Patients impaired fasting sugar ( base WHO ; fast blood sugar &gt; 110 mg/dl 6.1 mmol/l ) repeat blood analysis . 10 . Chromosomal abnormality medical `` syndrome '' ( Turner 's syndrome , Laron syndrome , Noonan syndrome , PraderWilli Syndrome , RussellSilver Syndrome , short stature homeoboxcontaining gene ( SHOX ) mutations/deletions skeletal dysplasia ) , exception septooptic dysplasia . 11 . Closed epiphysis . 12 . Concomitant administration treatment may effect growth anabolic steroid methylphenidate attention deficit hyperactivity disorder ( ADHD ) , exception hormone replacement therapy ( thyroxine , hydrocortisone , desmopressin ( DDAVP ) ) 13 . Children require glucocorticoid therapy ( e.g . asthma ) take dose great 400 Âµg/d inhale budesonide equivalent longer 1 month calendar year . 14 . Major medical condition and/or presence contraindication rhGH treatment . 15 . Known suspected HIVpositive patient , patient advance disease AIDS tuberculosis . 16 . Drug , substance , alcohol abuse . 17 . Known hypersensitivity component study medication . 18 . Other cause short stature coeliac disease , hypothyroidism rickets . 19 . The patient and/or parent/legal guardian likely noncompliant respect study conduct . 20 . Participation trial investigational agent within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Growth hormone deficiency ( GHD )</keyword>
	<keyword>r-hGH</keyword>
	<keyword>Long-acting</keyword>
</DOC>